

Cambridge University Press

0521858224 - Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech

Edited by Mariana Mazzucato and Giovanni Dosi

Table of Contents

[More information](#)

## Contents

<i>List of figures</i>	<i>page</i> ix
<i>List of tables</i>	xii
<i>List of contributors</i>	xiv
<i>Acknowledgments</i>	xvii
1 Introduction <i>Giovanni Dosi and Mariana Mazzucato</i>	1
<b>Part I Innovation and industry evolution</b>	<b>19</b>
2 Pharmaceutical innovation as a process of creative destruction <i>Frank R. Lichtenberg</i>	21
3 The evolution of pharmaceutical innovation <i>Paul Nightingale and Surya Mahdi</i>	73
4 Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals <i>Myriam Mariani</i>	112
5 Innovation and industry evolution: a comment <i>Louis Galambos</i>	145
<b>Part II Firm growth and market structure</b>	<b>161</b>
6 Heterogeneity and firm growth in the pharmaceutical industry <i>Elena Cefis, Matteo Ciccarelli, and Luigi Orsenigo</i>	163
7 Growth and diversification patterns of the worldwide pharmaceutical industry <i>Giulio Bottazzi, Fabio Pammolli, and Angelo Secchi</i>	208

Cambridge University Press

0521858224 - Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech

Edited by Mariana Mazzucato and Giovanni Dosi

Table of Contents

[More information](#)

viii		<i>Contents</i>
8	Entry, market structure, and innovation in a “history-friendly” model of the evolution of the pharmaceutical industry <i>Christian Garavaglia, Franco Malerba, and Luigi Orsenigo</i>	234
9	The growth of pharmaceutical firms: a comment <i>Boyan Jovanovic</i>	266
	<b>Part III Policy implications</b>	<b>275</b>
10	The effects of research tool patents and licensing on biomedical innovation <i>John P. Walsh, Ashish Arora, and Wesley M. Cohen</i>	277
11	Upstream patents and public health: the case of genetic testing for breast cancer <i>Fabienne Orsi, Christine Sevilla, and Benjamin Coriat</i>	327
12	Competition, regulation, and intellectual property management in genetically modified foods: evidence from survey data <i>Pierre Regibeau and Katharine Rockett</i>	346
13	Governance, policy, and industry strategies: pharmaceuticals and agro-biotechnology <i>Joyce Tait, Joanna Chataway, Catherine Lyall, and David Wield</i>	378
14	The dynamics of knowledge accumulation, regulation, and appropriability in the pharma-biotech sector: policy issues <i>Luigi Orsenigo, Giovanni Dosi, and Mariana Mazzucato</i>	402
	<i>Index</i>	432